H
Howard E. Rockette
Researcher at University of Pittsburgh
Publications - 158
Citations - 12564
Howard E. Rockette is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Otitis & Receiver operating characteristic. The author has an hindex of 53, co-authored 156 publications receiving 11947 citations.
Papers
More filters
Journal ArticleDOI
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.
Bernard Fisher,Norman Wolmark,Howard E. Rockette,Carol K. Redmond,Melvin Deutsch,D. Lawrence Wickerham,Edwin R. Fisher,Richard Caplan,Judith Jones,Harvey J. Lerner,Philip H. Gordon,Merrill I. Feldman,Anatolio B. Cruz,S Legault-Poisson,Marvin Wexler,Walter Lawrence,André Robidoux,Other Nsabp Investigators +17 more
TL;DR: Investigation of stratification variables employed in this study indicated that sex, and to a lesser extent age and Dukes stage, made individual contributions to the disease-free survival and the survival benefit from chemotherapy.
Journal ArticleDOI
The Benefit of Leucovorin-Modulated Fluorouracil as Postoperative Adjuvant Therapy for Primary Colon Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-03
Norman Wolmark,Howard E. Rockette,Bernard Fisher,D L Wickerham,Carol K. Redmond,Edwin R. Fisher,J Jones,Eleftherios P. Mamounas,L Ore,Nicholas J. Petrelli +9 more
TL;DR: Treating patients with Dukes' stage B and C carcinoma of the colon with leucovorin-modulated fluorouracil as adjuvant therapy significantly prolongs disease-free survival and results in a significant benefit relative to overall survival.
Journal ArticleDOI
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04)
Eleftherios P. Mamounas,S. Wieand,Norman Wolmark,Harry D. Bear,James N. Atkins,Kyunghee Song,J Jones,Howard E. Rockette +7 more
TL;DR: Patients with Dukes' B colon cancer benefit from adjuvant chemotherapy and should be presented with this treatment option, regardless of the presence or absence of other clinical prognostic factors.
Journal ArticleDOI
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Placebo-phase Trial
Chester V. Oddis,Ann M. Reed,Rohit Aggarwal,Lisa G. Rider,Dana P. Ascherman,Marc C. Levesque,Richard J. Barohn,Brian M. Feldman,Michael O. Harris-Love,Diane Koontz,Noreen Fertig,Stephanie S. Kelley,Sherrie L. Pryber,Frederick W. Miller,Howard E. Rockette +14 more
TL;DR: Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI, and individual CSMs improved in both groups throughout the 44-week trial.
Journal ArticleDOI
Randomized Trial of Postoperative Adjuvant Chemotherapy With or Without Radiotherapy for Carcinoma of the Rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
Norman Wolmark,H. Samuel Wieand,David M. Hyams,Linda H. Colangelo,Nikolay V. Dimitrov,Edward H. Romond,Marvin Wexler,David Prager,Anatolio B. Cruz,Philip H. Gordon,Nicholas J. Petrelli,Melvin Deutsch,Eleftherios P. Mamounas,D. Lawrence Wickerham,Edwin R. Fisher,Howard E. Rockette,Bernard Fisher +16 more
TL;DR: The addition of postoperative radiation therapy to chemotherapy in Dukes' B and C rectal cancer did not alter the subsequent incidence of distant disease, although there was a reduction in locoregional relapse when compared with chemotherapy alone.